Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25143773 | 1.00 | CRBN (0.46) | CRBNDDB1POLBDGAT1ADORA2A | |
| SCHEMBL30201866 | 0.86 | CRBN (0.50) | CRBNDDB1POLB | |
| SCHEMBL25196638 | 0.86 | CRBN (0.50) | CRBNDDB1POLB | |
| SCHEMBL25074066 | 0.86 | CRBN (0.50) | CRBNDDB1POLB | |
| SCHEMBL25501893 | 0.85 | CRBN (0.51) | CRBNDDB1POLBKCNH2 | |
| SCHEMBL31382394 | 0.85 | CRBN (0.58) | CRBNDDB1POLB | |
| SCHEMBL25190647 | 0.84 | CRBN (0.46) | CRBNDDB1POLBDGAT1KCNH2 | |
| SCHEMBL25192140 | 0.84 | CRBN (0.46) | CRBNDDB1POLBDGAT1KCNH2 | |
| SCHEMBL30441775 | 0.84 | CRBN (0.46) | CRBNDDB1POLBDGAT1KCNH2 | |
| SCHEMBL25143772 | 0.83 | CRBN (0.47) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | GILEAD SCIENCES, INC. | 2024-12-19 | — | — | US | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117813307-A | Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023023255-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | CRBN 2455/4885DDB1 2477/4885POLB 2671/4885 |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | IRAK1, IRAK2, IRAK4 | CRBN 296/4885DDB1 635/4885POLB 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.